David Dubin, MD
Radiation Oncology · Englewood, NJNPI 1205881703
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $648 of the $967 with a category attached, or 67.0%. Merck accounts for 67.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $724 and has fallen 90.4% since, to $70 in 2024.
Across 13 payments — averaging $74.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$648
- Elekta, Inc.$70
- Myovant Sciences Inc.$52
- Palette Life Sciences, Inc.$40
- Brainlab, Inc.$38
- Varian Medical Systems, Inc.$24
- plus $96 from 5 others
What the payments were for
- Consulting fees$64867%
- Food & beverage$31933%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $648 |
| Elekta, Inc. | 1 | $70 |
| Myovant Sciences Inc. | 2 | $52 |
| Palette Life Sciences, Inc. | 2 | $40 |
| Brainlab, Inc. | 1 | $38 |
| Varian Medical Systems, Inc. | 1 | $24 |
| Bayer | 1 | $24 |
| Boston Scientific | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $16 |
| AstraZeneca | 1 | $14 |
How this compares
$967 in reported general payments places this provider in the 65th percentile of 132 radiation oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 27 | $11,323 |
| Tamsulosin Hcl | 81 | $666 |
| SsdSilver Sulfadiazine | 19 | $428 |
| Bicalutamide | 20 | $151 |
| Finasteride | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Englewood
- Mei ZhangEnglewood$689
- Michael GreenbergCherry Hill$335K
- Glen GejermanHackensack$180K
- Marc RudoltzWest Orange$166K
- Salma JabbourNew Brunswick$163K
- Edward SoffenMonroe Twp$50K
- Adnan DanishWayne$45K
- Timothy ChenPennington$43K
- Brett LewisHackensack$23K
- Sang SimLong Branch$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.